ATRA - Atara Biotherapeutics, Inc.
| Previous Close | 23.16 |
| Open | 23.29 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1800 |
| Day's Range | 22.05 - 23.65 |
| 52 Week Range | 22.05 - 52.74 |
| Volume | 613,770 |
| Avg. Volume | 606,104 |
| Market Cap | 1.088B |
| Beta (3Y Monthly) | 3.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.62 |
| Earnings Date | Nov 2, 2017 - Nov 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 47.50 |
- Thomson Reuters StreetEvents•4 days ago
Edited Transcript of ATRA earnings conference call or presentation 9-May-19 12:30pm GMT
Q1 2019 Atara Biotherapeutics Inc Earnings Call
- GlobeNewswire•8 days ago
Atara Biotherapeutics Announces Presentations Highlighting Tab-cel® and Mesothelin-Targeted CAR T Clinical Results at American Society of Clinical Oncology (ASCO) Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 15, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- GlobeNewswire•9 days ago
Atara Biotherapeutics Announces Presentation of Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN)
SOUTH SAN FRANCISCO, Calif., May 15, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- Motley Fool•14 days ago
Why Atara Biotherapeutics Stock Is Imploding Today
Investors are growing impatient with this clinical-stage biotech.
- Associated Press•15 days ago
Atara Biotherapeutics: 1Q Earnings Snapshot
The South San Francisco, California-based company said it had a loss of $1.44 per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- GlobeNewswire•15 days ago
Atara Biotherapeutics Announces First Quarter 2019 Financial Results and Recent Operational Progress
SOUTH SAN FRANCISCO, Calif., May 09, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- ACCESSWIRE•15 days ago
Atara Biotherapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 9, 2019 / Atara Biotherapeutics, Inc. (NASDAQ: ATRA ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 9, 2019 at 8:30 AM ...
- GlobeNewswire•16 days ago
Atara Biotherapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019
SOUTH SAN FRANCISCO, Calif., May 07, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- Motley Fool•17 days ago
Where Will Gilead Sciences Spend Its Cash?
Atara Biotherapeutics and Exelixis might be top takeover targets for the biotech giant.
- Insider Monkey•21 days ago
Here is What Hedge Funds Think About Atara Biotherapeutics Inc (ATRA)
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and their long-term focus allows us to profit from the recent […]
- Motley Fool•last month
2 Best Biotech Buyout Plays
Atara Biotherapeutics and Crispr Therapeutics stand out as strong takeover candidates. Here's why.
- GlobeNewswire•2 months ago
Atara Biotherapeutics Presents Off-the-Shelf, Allogeneic CAR T Preclinical Results at the American Association of Cancer Research (AACR) Annual Meeting 2019
Epstein-Barr virus-specific T cells were engineered to express second-generation CD19 chimeric antigen receptors, eliminated in vitro alloreactivity and inhibited tumor growth.
- GlobeNewswire•2 months ago
Atara Biotherapeutics Announces Collaborator Presentation of Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma
Memorial Sloan Kettering Cancer Center collaborators presented results that a regionally delivered mesothelin-targeted, autologous CAR T was well-tolerated and showed.
- Simply Wall St.•2 months ago
The Atara Biotherapeutics (NASDAQ:ATRA) Share Price Has Gained 122%, So Why Not Pay It Some Attention?
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company that is really flourishing, you canRead More...
- GlobeNewswire•3 months ago
Atara Biotherapeutics to Participate in Upcoming Conferences
SOUTH SAN FRANCISCO, Calif., March 07, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- American City Business Journals•3 months ago
How attacking a virus in cancer patients helped a Peninsula company target MS
Cancer remains the company's main focus, but it also is pushing to transform treatment of multiple sclerosis.
- GlobeNewswire•3 months ago
Atara Biotherapeutics Announces Presentations Highlighting Next-Generation CAR T Platform and Mesothelin-Targeted CAR T Clinical Results at American Association of Cancer Research (AACR) Annual Meeting 2019
Atara to present off-the-shelf, allogeneic CAR T proof-of-concept results demonstrating Epstein-Barr virus (EBV)-specific T cells expressing chimeric antigen receptors Memorial.
- GlobeNewswire•3 months ago
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Progress
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- GlobeNewswire•3 months ago
Consolidated Research: 2019 Summary Expectations for T-Mobile US, WestRock, Shake Shack, Atara Biotherapeutics, CorVel, and Transdigm Group — Fundamental Analysis, Key Performance Indications
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- American City Business Journals•4 months ago
At biotech's big event, a chance for execs to shape LGBTQ diversity on boards
As corporate diversity issues are in the spotlight, a small group will assemble at the J.P. Morgan Healthcare Conference to build a network of current and potential LGBTQ board members.
- GlobeNewswire•5 months ago
Atara Biotherapeutics to Participate in the 37th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- Zacks•5 months ago
Company News For Jan 4, 2019
Companies in the news are: BMY, CELG, DAL, TRCO and ATRA
- Motley Fool•5 months ago
Why Delta Air Lines, Atara Biotherapeutics, and Skyworks Solutions Slumped Today
Find out what made these high-flying stocks lose altitude.
